Search results
Showing 106 to 120 of 169 results for urinary tract infection
Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (IPG30)
Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.
View recommendations for IPG30Show all sections
Evidence-based recommendations on transurethral water-jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia. This involves injecting a high-speed jet of water into the prostate to destroy some of the prostate tissue and widen the urethra.
View recommendations for IPG770Show all sections
Fetal vesico–amniotic shunt for lower urinary tract outflow obstruction (IPG202)
Evidence-based recommendations on fetal vesico–amniotic shunt for lower urinary tract outflow obstruction. This involves inserting a cannula through the mother's abdominal and uterine walls into the amniotic cavity and subsequently into the bladder of the fetus.
View recommendations for IPG202Show all sections
Sections for IPG202
Electrocautery cutting balloon treatment for pelviureteric junction obstruction (IPG324)
Evidence-based recommendations on electrocautery cutting balloon treatment for pelviureteric junction obstruction. This involves widening the renal pelvis by inserting a catheter with a balloon and wire into the urinary tract.
View recommendations for IPG324Show all sections
Sections for IPG324
Evidence-based recommendations on prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia in adults. This involves blocking the blood vessels supplying the prostate with tiny plastic particles.
View recommendations for IPG611Show all sections
your mesh was for stress urinary incontinence, see NICE's decision aid on treating complications from mesh used for stress...
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a docetaxel-containing regimen.
This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.
Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)
Evidence-based recommendations on fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction. This involves inserting a tube with a flexible camera through small cuts in the mother's abdomen to identify and open any blockage.
View recommendations for IPG205Show all sections
Sections for IPG205
NICE has developed a medtech innovation briefing (MIB) on URO17 for detecting bladder cancer .
Sacral nerve stimulation for urge incontinence and urgency-frequency (IPG64)
Evidence-based recommendations on sacral nerve stimulation for urge incontinence and urgency-frequency. This involves placing electrodes and connecting them to an implantable pulse generator.
This guideline covers identifying and caring for adults who are malnourished or at risk of malnutrition in hospital or in their own home or a care home. It offers advice on how oral, enteral tube feeding and parenteral nutrition support should be started, administered and stopped. It aims to support healthcare professionals identify malnourished people and help them to choose the most appropriate form of support.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.